Ignite Creation Date:
2024-05-11 @ 8:31 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06406348
Status:
RECRUITING
Last Update Posted:
2024-06-14
First Post:
2024-05-06
Brief Title:
A Phase 1 Trial to Assess Safety Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants
Sponsor:
Aliada Therapeutics
Organization:
Aliada Therapeutics
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Phase 1 Single Ascending Dose Trial to Assess the Safety Tolerability and Pharmacokinetic Effects of ALIA-1758 in Healthy Participants
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 1 first in human FIH double-blind placebo-controlled single ascending dose SAD trial to assess the safety tolerability and pharmacokinetics PK of intravenously IV or subcutaneously SC injected ALIA-1758 in healthy male and female participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None